

inside blood

15 SEPTEMBER 2007 | VOLUME 110, NUMBER 6

● ● ● RED CELLS

Comment on Lin et al, page 2182

Iron can boost hepcidin both ways


Prem Ponka and Bill Andriopoulos MCGILL UNIVERSITY

In this issue of *Blood*, Lin and colleagues report that in freshly isolated murine hepatocytes, holotransferrin can stimulate hepcidin production and that holotransferrin regulates hepcidin mRNA levels through a hemojuvelin–BMP2/4–dependent pathway.

Iron is indispensable for life, but unless appropriately protected, it plays a key role in the formation of toxic oxygen radicals that can attack all biological molecules. Hence, mammals evolved various regulatory mechanisms that, under normal conditions, maintain iron at appropriate levels both in their cells and in the whole organism. Physiologically, all plasma iron (~ 3 mg in humans) is bound to transferrin, which transports iron within the body between sites of utilization, storage, and absorption. The turnover of plasma iron is approximately 30 mg per day and, normally, approximately 80% of this iron is transported to the bone marrow where erythroid cells use the metal for the synthesis of hemoglobin. At the end of an erythrocyte's life, it is phagocytosed by macrophages of the reticuloendothelial system. Within the macrophage, heme is catabolized via heme oxygenase 1, which liberates the metal from its confinement within the protoporphyrin ring. Iron is then released from macrophages into the circulation with a rate that matches the rate with which erythroid cells take up iron from transferrin. Iron is exported from the cells via ferroportin, with the ferroxidase activity of ceruloplasmin facilitating the movement of iron across the membrane of macrophages. About 1 mg of dietary iron is absorbed per day, and the total iron balance is maintained by a daily

loss of 1 mg via non-specific mechanisms. Ferroportin, in conjunction with the ceruloplasmin homolog hephaestin, is involved in the exit of iron from enterocytes into the circulation.¹

Recent research has identified hepcidin, the peptide hormone synthesized in the liver, as the principal regulator of organismal iron homeostasis. Although hepcidin synthesis is affected by hypoxia, erythropoietic activity, and inflammatory cytokines,^{2,3} the principal regulator of hepcidin production is most likely iron. It is now well established that iron administration to healthy humans or mice induces the synthesis of hepcidin, which, in turn, inhibits the release of iron from duodenal epithelial cells as well as macrophages involved in the recycling of hemoglobin iron. However, thus far, in vitro studies using either hepatoma cell lines or primary hepatocytes have failed to demonstrate



Central role of hepcidin in organismal iron homeostasis. Cell-associated, GPI-linked hemojuvelin (HJV) is proposed to act as a coreceptor for bone morphogenetic protein (BMP) ligands and BMP receptors (BMP-Rs). Interaction of HJV with BMP ligands and 2 BMP-Rs on the cell surface generates an active signaling complex. This complex subsequently activates the intracellular SMAD signaling pathway to induce hepcidin expression. Hepcidin, a peptide secreted by the liver, promotes internalization and degradation of the iron exporter ferroportin (FPN). The pathway by which HFE and transferrin receptor 2 (Tfr2) control the expression of hepcidin is unclear. Importantly, mutations in HJV, HFE, or Tfr2 lead to inappropriately low levels of hepcidin. Dcytb indicates duodenal cytochrome b; DMT1, divalent metal transporter 1. This figure is a modified version of that published in Dunn et al,² copyright Elsevier; adapted with permission by Alice Y. Chen.

increased synthesis of hepcidin in response to iron loading.³

Lin and colleagues have provided evidence that the inability of hepatocytes to synthesize hepcidin in response to diferric transferrin was due to the fact that previous studies used primary hepatocytes cultured for 48 hours before

treatment with holotransferrin. In contrast, this report has clearly demonstrated that diferric transferrin, but not apotransferrin, causes an increase in hepcidin mRNA levels in freshly isolated murine primary hepatocytes.

However, it should be noted that the increase in hepcidin mRNA levels following the addition of holotransferrin to freshly isolated hepatocytes is relatively minor.

Hemojuvelin mutations result in juvenile hemochromatosis, which is indistinguishable from that caused by hepcidin mutations; furthermore, hemojuvelin has been shown to participate in the complex regulation of hepcidin. The authors therefore examined whether iron affects hepcidin production via a hemojuvelin-dependent pathway. Hemojuvelin exists both as a soluble and a cell-associated GPI-linked form, the latter being a BMP coreceptor that enhances hepcidin signaling in liver cells.

As shown in the figure, BMP induction of hepcidin is enhanced via hemojuvelin in hepatocytes through a BMP/SMAD-dependent pathway. Its role as an enhancer may act to finely tune the BMP-mediated induction of hepcidin expression. Lin and colleagues have succeeded in identifying a component missing from previous *in vitro* studies: namely, the role of iron in the BMP/hemojuvelin/SMAD-mediated induction of hepcidin synthesis.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

REFERENCES

1. Andrews NC, Schmidt PJ. Iron homeostasis. *Annu Rev Physiol.* 2007;69:69-85.
2. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. *Trends Cell Biol.* 2007;17:93-100.
3. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. *Annu Rev Nutr.* 2006;26:323-342.

● ● ● GENE THERAPY

Comment on Cattoglio et al, page 1770

RIS defines risk

Utpal P. Davé VANDERBILT UNIVERSITY MEDICAL CENTER

In this issue of *Blood*, Cattoglio and colleagues examine retroviral integration site (RIS) preferences in CD34⁺ cells and conclude that gamma-retroviruses carry a higher risk for insertional mutation than lentiviruses.

To date, 4 out of 10 patients treated with Necker Hospital's gene-therapy protocol for X-linked severe combined immunodeficiency (X-SCID) have developed T-cell leukemia.¹ The mechanism that caused these serious complications was retroviral insertional mutagenesis. In every case, the gene-therapy vector (gamma-retrovirus-based) inserted and deregulated a nearby oncogene. Most remarkably, in 2 patients, the vector inserted and inappropriately activated the expression of a known T-cell oncogene, LIM-domain-only 2 (*LMO2*). In light of these complications, regulatory agencies expect improved understanding of the risk of this genotoxicity.²

So what is the probability of a retroviral vector inserting near an oncogene or tumor suppressor? Like so many things in biology, the answer is complicated and seems to depend on cell context. We now know that retro-

viruses have integration-site preferences. Studies in HeLa cells showed that gamma-retroviruses prefer to integrate near transcriptional start sites (26% of total sites analyzed) whereas lentiviruses prefer to insert within introns.³ Now, Cattoglio and colleagues present similar findings in CD34⁺ cells. They transduced CD34⁺ cells with either gamma-retroviral or lentiviral vectors *in vitro* and harvested genomic DNA 1 to 12 days after infection. Integration sites were then cloned and mapped from this largely unselected population using standard methods. They analyzed 1030 gamma-retroviral integrations and 869 lentiviral integrations. As in the HeLa study, they found a gamma-retroviral bias for transcriptional start sites (29% of total) and for actively transcribed genes. Lentiviral integrations were also biased toward actively transcribed genes, but for intragenic rather than transcriptional start sites.

The most striking result, however, was the discovery of numerous recurrent integrations in this unselected population of cells. Cattoglio and colleagues show that 20% of the total gamma-retroviral integrations were in the same locus, whereas 12.5% of the lentiviral integrations were recurrent. Wu et al reported recurrent gamma-retroviral integrations in HeLa cells, but at a lower frequency (12%).⁴ Additionally, Cattoglio and colleagues show that many of the recurrent gamma-retroviral integrations were cancer associated. In contrast, recurrent lentiviral integrations did not involve a statistically significant number of cancer-associated genes. Cattoglio and colleagues refer to these recurrent integrations as "hotspots," but it remains to be seen whether the exact same genomic regions will be targeted in other studies. These results also contrast with *in vivo* analyses of transduced cells in animal models in which recurrent integrations are infrequent, except in specific loci conferring selective growth advantage.² Furthermore, if hotspots in cancer-associated genes existed in murine hematopoietic stem cells, then one would anticipate a high frequency of leukemias arising from marrow transduced with empty vectors, which is a rare occurrence under standard conditions. An alternate interpretation is that the human genome is highly constrained for integration in cultured CD34⁺ cells. In other words, there are some parts of the genome that are unavailable to gamma-retroviral integration. This raises the question of whether accessibility of the genome to integration can be altered by cell-culture conditions.

Investigation of these possibilities and additional RIS analyses will help define the risks of retroviral gene therapy.

Conflict-of-interest disclosure: The author declares no competing financial interests. ■

REFERENCES

1. European Society of Gene and Cell Therapy Newsletter. Available at <http://www.esgct.org/newsletter.cfm>. Accessed May 23, 2007.
2. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. *Mol Ther.* 2006;13:1031-1049.
3. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. *Science.* 2003;300:1749-1751.
4. Wu X, Luke BT, Burgess SM. Redefining the common insertion site. *Virology.* 2006;344:292-295.



blood[®]

2007 110: 1703-1704
doi:10.1182/blood-2007-06-095224

Iron can boost hepcidin both ways

Prem Ponka and Bill Andriopoulos

Updated information and services can be found at:
<http://www.bloodjournal.org/content/110/6/1703.full.html>

Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>